CIK 0001439222
- Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 14 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-18 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion · Performance share units | −3,000 | 9,000 | ||
| 2026-06-18 | Milanova Tsveta Chief Commercial Officer | Grant or award · Restricted stock units | +3,000 | 3,000 | ||
| 2026-04-02 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion 10b5-1 | +8,500 | 50,091 | ||
| 2026-04-02 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 | −3,262 | $34.71 | $113K | 46,829 |
| 2026-04-02 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion · Performance share units 10b5-1 | −8,500 | 8,500 | ||
| 2026-03-02 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion 10b5-1 | +5,666 | 40,459 | ||
| 2026-03-02 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 | −1,681 | $28.96 | $49K | 38,778 |
| 2026-03-02 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion 10b5-1 | +4,000 | 42,778 | ||
| 2026-03-02 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 | −1,187 | $28.96 | $34K | 41,591 |
| 2026-03-02 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion · Restricted stock units 10b5-1 | −5,666 | 5,667 | ||
| 2026-03-02 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion · Restricted stock units 10b5-1 | −4,000 | 8,000 | ||
| 2026-03-01 | Milanova Tsveta Chief Commercial Officer | Grant or award · Restricted stock units 10b5-1 | +14,000 | 14,000 | ||
| 2026-03-01 | Milanova Tsveta Chief Commercial Officer | Grant or award · Stock options (right to buy) 10b5-1 | +52,000 | 52,000 | ||
| 2026-01-05 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion 10b5-1 | +8,475 | 37,665 | ||
| 2026-01-05 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 | −2,872 | $27.02 | $78K | 34,793 |
| 2026-01-05 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion · Restricted stock units 10b5-1 | −8,475 | 0 | ||
| 2025-12-30 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion 10b5-1 | +6,000 | 32,122 | ||
| 2025-12-30 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 | −2,932 | $27.09 | $79K | 29,190 |
| 2025-12-30 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion · Performance share units 10b5-1 | −6,000 | 0 | ||
| 2025-06-24 | Milanova Tsveta Chief Commercial Officer | Exercise or conversion 10b5-1 | +6,000 | 28,892 |
Page 1 of 3 · 43 trades